Ipsen

Historical price data

Ipsen is a well-established French biopharmaceutical company that has evolved from its 1986 founding to become a global leader in specialty care medicines. The company focuses on areas of high unmet medical need across oncology, rare diseases, and neuroscience, with particular expertise in neuroendocrine tumors, rare liver conditions like PBC, and neurological disorders including spasticity. Ipsen's strategy emphasizes targeted innovation and strategic partnerships to accelerate drug development and expand their pipeline. The company has demonstrated strong financial performance with consistent growth and maintains a robust balance sheet to support continued R&D investments and pipeline expansion.

Ipsen leverages over 30 years of specialized expertise in oncology (particularly neuroendocrine tumors), neuroscience (toxins and neurological conditions), and rare diseases to develop innovative specialty care medicines. The company combines advanced drug development capabilities with regulatory expertise and global commercial infrastructure to address high unmet medical needs.

294 drugs in pipeline, 101 in Phase 3

Ipsen competes with major pharmaceutical companies like Novartis, Roche, and AbbVie in oncology and neuroscience, while facing specialized biotech competitors like BioMarin and Sarepta in rare diseases. The company differentiates itself through deep therapeutic expertise, established commercial infrastructure, and strategic focus on high-value specialty areas rather than competing across broad therapeutic categories.